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Summary 
Patients  with primary biliary cirrhosis  frequently  develop autoantibodies  directed  to gp210,  a 
major glycoprotein of the nuclear pore complex. This protein contains a large glycosylated cis- 
ternal domain, a single transmembrane segment, and a short cytoplasmic tail. It has been previ- 
ously shown  that autoantibodies  from primary biliary cirrhosis  patients  exclusively react with 
the  cytoplasmic tail.  We demonstrate  that autoantibodies  against gp210 recognize  at least two 
different epitopes.  4 out of 12 anti-gp210 positive sera reacted with the fragment consisting of 
the  cytoplasmic tail,  and  8  sera targeted  a novel epitope located within  the large glycosylated 
lumenal  domain.  Moreover,  our data prove that carbohydrate moieties are an essential part of 
this  novel  epitope.  We  propose,  therefore,  that  future  screening  assays should  be performed 
with antigens possessing both epitopes to detect all sera with anti-gp210  specificity. 
A 
bout one third of patients with primary biliary cirrho- 
sis  (PBC)  have  autoantibodies  that  recognize  gp210, 
an integral glycoprotein of the nuclear pore complex (1-4). 
"Mature"  gp210  is  composed  of three  main  domains.  A 
large  1,783-amino  acid amino-terminal  domain  is located 
in  the perinuclear  space between  the  outer  and inner  nu- 
clear membrane. A  short 20-amino  acid hydrophobic  seg- 
ment  spans  the  nuclear  membrane  and  a  58-amino  acid 
carboxy-terminal tail domain faces the  cytoplasm (5,  6).  It 
has  been  shown  that  gp210  contains  high  mannose-type 
oligosaccharides.  Carbohydrate  moieties  contribute  5%  of 
the mass of g p210 and are restricted to the amino-terminal 
domain (5). Since the three domains ofgp210 greatly differ 
from  each  other  structurally,  it  is  of interest  whether  the 
autoantibodies  directed  against  gp210  recognize  a  specific 
domain of this protein.  Recently,  it has been reported that 
autoantibodies  from  PBC  patients  exclusively  recognize  a 
short region within the cytoplasmic tail ofgp210  (7). In the 
present study, we demonstrate  that the anti-gp210  autoan- 
tibodies are directed against at least two antigenic determi- 
nants:  one  located  in  the  cytoplasmic  and  another  in  the 
large lumenal  domain  of gp210  protein.  Furthermore,  the 
autoantibodies  exclusively recognize  the glycosylated form 
of the amino-terminal domain of gp210 protein, indicating 
that carbohydrate residues are an integral part of this novel 
epitope. 
Materials and Methods 
Patients.  Sera were  obtained from 43  patients with  primary 
biliary cirrhosis  and 20  healthy blood donors.  The  diagnosis  of 
primary biliary cirrhosis  was based on accepted clinical,  biochem- 
ical, and histological criteria. 
Chemical Reagents.  Routine  chemical reagents were obtained 
from  either  the  United  States  Biochemical  Corp.  (Cleveland, 
OH) or Sigma Chemical Co. (St. Louis, MO). 
Isolation  of Nuclei and  Nuclear Pore Complea~Lamina  Fraction 
(NPC).  To avoid proteolytic degradation of proteins,  all isola- 
tion steps were performed at 4~  in the presence of protease in- 
hibitors. 
The nuclei  were isolated as described previously (8). Briefly, 
HeLa cells were PBS washed,  swollen for 10 rain in hypotonic 
buffer, and spun down. The pellet was suspended again in hypo- 
tonic buffer and homogenized after addition  of NP-40  and so- 
dium deoxycholate to a final concentration of 1% and 0.5%,  re- 
spectively. Then nuclei were pelleted through sucrose cushion. 
Subsequently, the NPC was prepared according to the method 
described by Dwyer and Blobel (9). In short,  the isolated nuclei 
were  digested  with  DNase  I  at  pH  8.5,  then  redigested  with 
DNase I and pancreatic RNase at a neutral pH and extracted in 
two  consecutive steps,  first with high salt buffer and thereupon 
with buffer containing nonionic  detergents.  This yielded an in- 
soluble pellet defined as the  NPC.  After treatment of the pellet 
with buffer containing high concentration of monovalent cations 
and  nonionic  detergents,  proteins  of the  nuclear pores became 
soluble. 
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finity chromatography on lentil lectin-Sepharose (Pharmacia Fine 
Chemicals, Uppsala, Sweden). Nuclear pore proteins solubilized 
at concentration N2 mg/ml in high salt buffer (500  mM NaC1, 
20 mM Hepes, pH 7.35,  1 mM MgCl2, 1 mM DTT, and 1 mM 
PMSF)  containing 2% Triton X-100  were loaded on preequili- 
brated lentil lectin-Sepharose. The column was then washed with 
at least 20 vol of high salt buffer containing 0.1%  Triton X-100. 
gp210 protein was  eluted with high salt buffer containing 1.2 M 
methyl-ot-D-mannopyranoside and 0.1% Triton X-100. 
Electrophoretic Separation of Proteins.  Proteins  of nuclear sub- 
fraction or purified proteins were separated by one-dimensional 
PAGE on 10 or 13% SDS slab gels, as described by Laemmli (10). 
After electrophoretic separation, proteins were detected by Coo- 
massie blue R-250 or silver staining. 
lmmunoblotting.  Proteins separated on slab gels were electro- 
phoretically transferred onto membranes  (Bio Rad Laboratories, 
Richmond, CA) and stained by Ponceau S. The blots were satu- 
rated with 3% BSA in PBS, then probed with patients sera diluted 
1:500,  extensively washed,  and  incubated  with  anti-human  Ig 
coupled to  horseradish peroxidase (HRP)  at a  1:2,000  dilution. 
The reactive antigens were detected by HRP-hydrogen peroxide 
catalyzed oxidation of luminol under  alkaline conditions using 
ECL  Western  blotting detection  reagents  (Amersham  Interna- 
tional,  Little  Chalfont,  U.K.)  and  X-Omat  S  film  (Eastman 
Kodak Co., Rochester, NY). 
Limited Proteolysis of gp210  Glycoprotein.  Isolated NPCs were 
resuspended at ~0.5  mg/ml protein in 0.25 M  sucrose, 20 mM 
Hepes, pH 7.35,  1 mM EDTA, and 1 mM DTT, and were incu- 
bated with  papain immobilized on  Sepharose  (Pierce Chemical 
Co., Rockford, IL) at 4~  for 5,  15, or 30 min. The reaction was 
stopped by removal of papain-Sepharose and  adding PMSF  (1 
mM), N-ethylmaleimide (2 mM), and leupeptin and pepstatin (1 
I~M each). The samples were centrifuged at 100,000 g for 1 h to 
yield pellets and supernatants. 
Deglycosylation of gp210  Protein.  Isolated NPCs  or  purified 
gp210 were suspended in 100 mM sodium citrate buffer, pH 5.5, 
0.1% SDS, and 3 mM DTT.  Protease inhibitors were added to a 
final concentration as follows: 0.5 mM PMSF, 0.7 I~g/ml pepsta- 
tin, 0.5  ~g/ml leupeptin,  1  I~g/ml aprotinin, and 0.1  mM  Pe- 
fabloc.  Then  endoglycosidase H  (Boehringer  Mannheim  Bio- 
chemicals, Indianapolis, IN) was added at a concentration of 50 
mU/700  Ixg protein, and the incubation was performed for 14 h 
at 37~  After deglycosylation, samples were ethanol precipitated 
and submitted for PAGE and immunoblotting. 
Covalent Immobilization of  gp210  Protein.  Purified gp210 pro- 
tein  was  immobilized on  Mini-Leak-Medium beads  (Kem.En- 
Tec,  Copenhagen,  Denmark)  according  to  the  manufacturer's 
protocol.  Mini-Leak  is  a  divinyl  sulfone--activated matrix  of 
spherical agarose especially designed for gentle immobilization of 
biomolecules, gp210  dissolved in PBS at a  concentration of 0.5 
mg/ml was added to the activated matrix and diluted with cou- 
pling buffer containing 30% polyethylene glycol 20,000 (PEG) to 
a final concentration of 10% PEG and incubated overnight. The 
supernatant was discarded, then the matrix was washed and incu- 
bated with 0.2 M  ethanol amine/HC1, pH 9.0, for 4 h  to block 
excess active groups. Coupling yield was determined by measure- 
ment of OD at 280 nm before and after coupling reaction. 
Isolation  of Anti-gp210  Antibodies by  Immunoaffinity Chroma- 
tography.  300 p~l of patient serum fivefold diluted with PBS was 
loaded on  preequilibrated gp210  affinity column.  The  column 
was washed with PBS until the basic OD level has been reached. 
Then bound autoantibodies were stepwise eluted with 150 raM, 
350 raM, and 1 M  NaC1 in 0.1 M  phosphate buffer, pH 3.0, and 
immediately neutralized with 2 M Tris, pH 9.0. 
Results  and Discussion 
We examined sera from 43 patients with PBC.  12 serum 
samples  that  recognized  on  immunoblots  gp210  purified 
from HeLa cells were used for further experiments, gp210 
was treated with papain, known to cleave this protein in a 
region of high papain sensitivity close to  the hydrophobic 
transmembrane domain (5). By papain treatment, two poly- 
petides were  generated:  an  amino-terminal fragment with 
molecular mass of~170  kD and a carboxy-terminal peptide 
of ~30  kD.  These  degradation products were  then  tested 
in  immunoblotting  experiments.  8  of 12  sera  exclusively 
recognized the  170-kD  amino-terminal fragment (Fig. 1 a, 
serum B), while 4 sera reacted only with the 30-kD peptide 
(Fig.  1  b,  serum  A).  The  170-kD  polypeptide contained 
carbohydrate  moieties  as  evidenced  by  its  ability to  bind 
lentil lectin (not shown).  To clarify whether these moieties 
play a  role in the immune  reaction,  the  gp210 was exten- 
sively treated  with  endoglycosidase H,  known  to  specifi- 
cally hydrolyze high  mannose  type N-linked oligosaccha- 
rides. This resulted in a marked reduction of the molecular 
mass of gp210 and completely abolished its binding to lentil 
lectin.  Concomitantly,  the  reactivity of autoantibodies to- 
wards the antigen changed dramatically, All of the sera that 
reacted with  the  amino-terminal  170-kD  fragment  didn't 
recognize the deglycosylated  form ofgp210 (Fig. 2, sera 4-8). 
On the other hand, the deglycosylation ofgp210, as expected, 
didn't affect its reactivity with the four sera that targeted an 
epitope  in  the  carboxy-terminal 30-kD  fragment  (Fig.  2, 
Figure  1.  Reactivity  of anti-gp210-positive PBC  sera with  papain- 
generated fragments of gp210 protein,  gp210 protein  partially digested 
with papain immobilized on Sepharose was separated by SDS-PAGE and 
submitted for immunoblotting. To achieve optimal resolution of corre- 
sponding proteins, the high molecular weight fragment was separated on 
10% polyacrylamide gels (a) and the small fragment was resolved on 13% 
polyacrylanfide  gels (b) 1.5 I.tg of untreated gp210 or 5 l~g ofpapain di- 
gested gp210 was loaded pro lane. Human sera were used at a 1:500 dilu- 
tion. Serum A doesn't react with the 170-kD fragment (a), but recognizes 
the 30-kD fragment. (b) Serum B reacts with the  170-kD fragment (a), 
but not with the 30-kD fragment (b), 
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lated form of gp210 protein.  Only sera 1-3 are able to react with gp210 
after endoglycosidase H treatment. As a positive control, untreated gp210 
was used (lane 1). Sera 1 and 5 correspond to sera A and B, respectively, 
in Fig. 1. 
Figure 5.  Reactivity  of glycosylated fragments of gp210 with affinity- 
purified  anti-gp210  antibodies.  Papain-generated  fragments  of gp210 
were purified on lentil lectin-Sepharose, loaded (3 Ixg) on 10% SDS-slab 
gels, and submitted for immunoblotting  using affinity-purified anti-gp210 
antibodies at a 1:500 dilution. Untreated gp210 (2 p~g) was applied in lane 
I as a control. Antibodies 4--6 were isolated from corresponding sera 4--6 
used in Fig. 2. 
Figure 3.  Purification of gp210 
glycoprotein.  Fractions  of  NPCs 
from HeLa cells were  resolved by 
SDS-PAGE on a 10% slab gel, and 
proteins  were  stained  with  Coo- 
massie blue 1K-250 (lanes M and 2- 
5) or silver stained (lane I).  (Lane 
M)  Molecular  weight  markers: 
myosin,  200  kD;  ~-galactosidase, 
116 kD, phosphorylase b, 97 kD; 
BSA, 66 kD, glutamic dehydroge- 
nase,  55  kD;  lactate  dehydroge- 
nase, 36  kD,  carbonic  anhydrase, 
31  kD,  trypsin  inhibitor,  21  kD. 
(Lanes  I  and  2)  Affinity-purified 
gp210. (Lane 3) Flowthrough frac- 
tion  of  lentil  lectin-Sepharose. 
(Lane  4)  NPC  extract  loaded  on 
lentil  lectin-Sepharose.  (Lane  5) 
NPC proteins. 
sera  1-3).  It is apparent that this autoepitope corresponds to 
that described by Nickowitz and Worman  (7). 
To  unequivocally  provide  evidence  that  the  protein 
fragment at  170 kD was recognized solely by specific anti- 
gp210  autoantibodies,  PBC  sera  were  submitted for  ffac- 
tionation on an immunoaffnity column. For this purpose, 
gp210  glycoprotein  purified  to  homogeneity  from  HeLa 
cells (Fig. 3,  lane  1) was immobilized on activated agarose 
beads.  This activated matrix is especially suitable for gende 
coupling of biomolecules  under  mild conditions.  Diluted 
PBC  sera  were  loaded  on preequilibrated  immunoaffinity 
column.  The  bulk  of proteins  flowed  through,  and  only 
anti-gp210-specific Igs were retained. The bound antibod- 
ies were eluted with salt in phosphate buffer at pH 3.0. The 
affnity-purified anti-gp-210 antibodies were  used for im- 
munoblotting. In these  experiments,  only the glycosylated 
fragments  of papain-digested  gp210  protein  were  used  as 
antigen. As shown in Fig. 4, after short papain treatment of 
gp210  protein,  two  glycosylated  fragments  of ",,180  and 
170  kD  were  purified  by  affnity  chromatography.  After 
longer digestion, only one glycosylated peptide  of 170  kD 
was  isolated.  Immunoblotting tests  using this  peptide  re- 
vealed  that  affinity-purified  anti-gp210  antibodies  react 
with  the  glycosylated  170-kD  fragment  of gp210  protein 
(Fig. 5). 
These  results,  summarized  in  Table  1,  clearly  demon- 
strate  that  autoantibodies  against  gp210  recognize  at  least 
two different epitopes: one located in the cytoplasmatic tail 
and  another  positioned  in  the  large  amino-terminal do- 
Figure  4.  Glycosylated fragments of papain-digested  gp210  protein. 
gp210 was papain digested for 5 or 15 min and loaded on lentil lectin- 
Sepahrose. Proteins eluted from the column were separated on 10% SDS 
slab gels and stained with Coomassie blue 1K-250. (Lanes 1 and 3) Purified 
gp210 submitted for papain digestion.  (Lane 2)  180- and 170-kD  frag- 
ments after 5 rain digestion. (Lane 4) 170-kD fragment after 15 rain di- 
gestion. 
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Table 1.  Spedficity of the Anti-gp2 I0 Antibodies 
Patients 
Recognized epitopes 
170 kD  30 kD 
gp210 
n  positive  Endo-H-  Endo-H  +  Endo-H-  Endo-H + 
PBC  43 
Controls  20 
12  8  0  4  4 
0  0  0  0  0 
Endo-H, endoglycosidase H. 
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moieties are an essential part of this novel epitope. 
There  is  an  obvious discrepancy between  our data  and 
results  that  have  been published  by Nickowitz  and  Wor- 
man (7).  However, since Nickowitz and Worman (7) have 
used a bacterially expressed gp210 fusion protein that,  due 
to the properties of the expression system, lacks posttransla- 
tional  modification,  they failed  to  detect  the  glycosylated 
epitope. In their screening system, 25 of 309 PBC sera (8%) 
have been shown to also recognize a full-length gp210 fu- 
sion protein as its cytoplasmic part.  It corresponds very well 
to our data, demonstrating that 4 of 43 PBC sera (9%) react 
with small cytoplasmic fragment ofgp210. 
Since  the  anti-gp210  antibodies  are  highly  specific  for 
PBC and its detection may be useful especially in diagnos- 
ing  individuals  without  antimitochondrial  antibodies  we 
suggest the use of gp210 purified from cells  of human ori- 
gin to ensure optimal assay conditions. 
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